Immunocore has raised more than $258m in an upsized offering and an additional $15m in a concurrent private placement.
Immunocore, a UK-based bispecific immunotherapy developer with roots at University of Oxford, issued approximately 9.94 million American Depositary Shares priced at $26 on Thursday to raise more than $258m in its IPO.
The company concurrently completed a $15m private placement, for total proceeds of more than $273m. It issued an additional 1.8 million shares and increased the price from $25 to $26 from its target a day earlier, and shares surged more than 66% to close at…
